InfiltrateID™ Quantification of the Immunocellular Content in the Tumor Microenvironment The emergence and success of immuno-oncology drugs in the treatment of several cancer types has transformed clinical practice. However, many patients do not respond to these drugs, compelling researchers and clinicians to broaden their search for biomarkers that can better [...]
Provider FAQs for NeXT Dx™ Test This document covers Provider FAQs and cancer genes of clinical importance covered by the Personalis NeXT Dx™ Test.
NeXT Dx™ Test Gene List Cancer Genes of Clinical Importance Single nucleotide variants, small insertions and deletions, copy number alterations, and gene fusions involving the genes in the NeXT Dx Test Gene List may be reported in the test. Genes in BOLD are those for which FDA approved drugs are [...]
SHERPA™ Bioinformatics Engine Systematic HLA Epitope Ranking Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Personalis’ ImmunoID NeXT™ enables a comprehensive survey [...]
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]
Personalis NeXT Dx™ Test Increasingly, oncologists and pathologists are utilizing information on genomic alterations in solid tumors, such as lung, colon, breast, melanoma, and prostate cancers, to help guide and optimize therapeutic options for patients including enrolling into cancer clinical trials. The Personalis NeXT Dx™ Test provides clinicians with a comprehensive [...]
RepertoireID™ Comprehensive Profiling of the Immune Repertoire within the Tumor Microenvironment RepertoireID, an analytics module of ImmunoID NeXT™, leverages RNA expression profiles to enable the detection and analysis of the top TCRα and TCRβ clonotypes, together with BCR heavy chain (BCRh) clonotypes found in the tumor microenvironment (TME) of patients’ tumors. [...]
NeoantigenID™ Comprehensive Identification of Putative Neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising targets for personalized cancer immunotherapies such as vaccines [...]
ImmunogenomicsID An analytical module of the ImmunoID NeXT PlatformTM Comprehensive Immunogenomic Characterization ImmunogenomicsIDTM, an analytical module of the ImmunoID NeXT Platform, characterizes critical areas of tumor and immune biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, tumor escape mechanisms, the adaptive and innate [...]
